Melanoma is the deadliest form of skin cancer and has an incidence that is rising faster than
any other solid tumor. Metastatic melanoma treatment has considerably progressed in the …

Importance In recent years, the management of metastatic melanoma has been transformed
by the emergence of immune checkpoint inhibitors and targeted therapies that significantly …

Both immune checkpoint inhibitors and molecularly targeted agents have dramatically
improved clinical outcomes for patients with metastatic melanoma. These two therapeutic …

Based on the complexity of the immune response to cancer and the mechanisms of tumor
evasion, it is likely that therapeutic modulation of multiple immune-mediated pathways will …

Background Immune checkpoint inhibitors and targeted therapies, two new class of drugs for
treatment of metastatic melanoma, have not been compared in randomized controlled trials …

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors
demonstrated their successful efficacy. Currently, the knowledge on the interaction between …

The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have
dramatically improved outcomes for patients with metastatic melanoma; however, not all …

In a relatively short period of time, treatment strategies for metastatic melanoma have
radically changed leading to an unprecedented improvement in patient survival. In this …

Immunotherapy for metastatic melanoma has a decades‐long history, and the relatively
recent use of checkpoint inhibitors has revolutionized treatment. Durable and sometimes …

Melanoma has always been described as an immunogenic tumor. Despite that, until 2011
the standard of care in metastatic melanoma was chemotherapy, with low response rates …